With an objective of not giving any such scope for price escalation as Martin Shkreli did for Daraprim generic drug, US Food and Drug Administration (US FDA) has turned very cautious on approvals to generic drugs. US FDA is now reviewing new applications for generic drugs, while ensuring no such lapses of price escalation.
Daraprim
Drug prescription firm Express Scripts Holding Co. found a way to offer a cheaper $1 alternative to Turing’s $750 a pill drug.
Turing Pharmaceuticals said that it won't cut the list price of the drug. However, it will negotiate discount price with hospital. Last September, Turing Pharmaceuticals raised the price of live-saving drugs, Daraprim by more than fifty times.
The overnight price hiked of Daraprim drug by the start-up, Turing Pharmaceutical is creating a big impact to the pharmaceutical sectors worldwide. The company which is own by a former hedge fund manager had acquired the right of the drug in August and immediately increases its price. The move is causing a backlash to pharmaceutical industry creating most of the shares down in a massive sell-off.
Subscribe to VCpost newsletter
Most Popular
- Nestle Cuts Sales Forecast as Shoppers Reject Price Hikes
- Social Security Payments Worth Over $4,800 To Go Out This Week; Here’s When You’ll Get Yours
- US Could See Another ‘Great Resignation’ as 3 in 10 Workers Plan To Quit in 2024: Survey
- Uber, Lyft Drivers Remain as Contractors After California Supreme Court Upheld Proposition 22
- Maersk Agrees to Settlement with US Labor Department After Firing Whistleblower
- Walmart Eyes $200 Million Investment in Autonomous Forklifts
- Delta’s CEO Flew to Paris for the Olympics While His Company Is Under Federal Investigation: Report
- Murdoch Empire Family Feud Could Upend the Media Industry, Possibly End Fox News